Jake Van Naarden, Lilly Oncology president and Loxo Oncology CEO
As Eli Lilly steams ahead with a closely-watched BTK drug, its rivals at Merck are taking a $275M write-down on delay
Merck was crystal clear from the beginning that its $2.7 billion investment in the ArQule buyout 2 years ago centered largely around the value of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
